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In the stomach, the epithelial stem cells are responsible for glandular homeostasis. 
These stem cells continuously undergo cellular proliferation and differentiation to 
balance death of senescent cells. Studies conducted on gastric cancers showed 
significant increase in parathyroid hormone like hormone (PTHLH). Moreover, both 
PTHLH along with parathyroid hormone (PTH) act as endogenous ligands for 
parathyroid hormone 1 receptor (PTH1R) which belongs to family B of G- protein 
coupled receptors (GPCRs). This receptor functions by mediating many different 
signaling pathways and the most studied pathway is the stimulation of cyclic adenosine 
mono-phosphate (cAMP) as second messenger.  
There are very little studies on understanding the normal function of gastric 
PTH1R. Specifically, how PTH1R and its ligands are associated with gastric cancer. 
The goal of this project is to investigate the expression of PTH1R in gastric epithelium, 
and to understand its possible function and signaling in maintaining gastric 
homeostasis. Firstly, gene expression analysis suggested that PTH1R is expressed in 
vivo in normal human stomach, and in mouse forestomach, corpus and antrum. In vitro 
studies on HeLa, and human embryonic kidney 293 cells (HEK293), also showed 
positive expression of PTH1R. However, mouse gastric epithelium progenitor cells 
(mGEP) and human gastric cancer cell line (AGS) showed no expression of PTH1R. 
To study the mechanism of PTH1R function, transfection of PTH1R plasmid was 
successfully conducted in mGEP and AGS cells. Next, we investigated the signaling 
pathways activated upon PTH1R stimulation. cAMP assay in transfected AGS cells 
treated with PTH1R agonist suggests activation of Gαs signaling pathway. On the other 
hand, transfected mGEP cells successfully activated ERK1/2 pathway. Morphological 
studies suggested difference in the cell morphology of transfected mGEP cells in 
which large cell to cell spaces was reported. Furthermore, cell viability results showed 
statistically a non-significant agonist and antagonist trend. Finally, several target genes 
were studied by Real-Time PCR. Low density lipoprotein receptor (LDLR) showed 
significant upregulation when comparing transfected and activated mGEP cells to 
control. However, calcium sensing receptor (CaSR), fibroblast growth factor 23 
(FGF23), interleukin-6 (IL-6), and Na+/H+ exchanger regulatory factor 1 (NHERF1) 






the stomach which might open new perspectives in studying PTH1R signaling in 
gastric cancer patients. This might set new therapeutic modalities for gastric cancer, 
especially since PTH1R agonists are used in treatment of bone cancer and 
osteoporosis.   
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6. Title and Abstract (in Arabic) 
 
 توازن الخاليا المعديةفي   PTH1R مستقبلدور ال
 صالملخ
 
تعد الخاليا والحفاظ على التوازن في المعدة.  عنالمعدة هي المسؤولة  بطانةخاليا 
الجذعية الموجودة في المعدة أساسية في تكاثر الخاليا وتمايزها. أظهرت الدراسات التي أجريت 
(. PTHLHالدرقية مثل هرمون ) الجار غدة على سرطانات المعدة زيادة كبيرة في هرمون
لمستقبالت ( كجزيئات PTHمع هرمون الغدة الدرقية ) PTHLHعمل يعالوة على ذلك ، 
(. GPCRsمن مستقبالت البروتين ) Bنتمي إلى عائلة والتي ت( PTH1R) هرمون الغدة الدرقية
المختلفة ، والمسار األكثر ارات بِل عن طريق التوسط في العديد من مسارات اإلشق  ت  س  يعمل هذا الم  
 .كرسول ثاني cAMP بتحفيز مسار المسار المتعلقهو دراسة
للمعدة. على وجه التحديد باالطبيعية  PTH1Rهناك القليل من الدراسات حول فهم وظيفة 
في  PTH1Rتواجد  ف من هذا المشروع هو بحثبسرطان المعدة. الهد PTH1R، كيف ترتبط 
في الحفاظ على التوازن المعدي. يوحي  PTH1R وفهم الوظيفة الممكنة للمستقبلدة ، المع أنسجة
 أجزاء معدة في واجدتي  PTH1Rوالكيمياء المناعية بأن  PCRستخدام إتحليل التعبير الجيني ب
( و خاليا mGEPخاليا المعوية الفأرية )ال. أشارت الدراسات المختبرية على المختلفة الفأر
عداد إتحدي تم . للتغلب على هذا الPTH1Rلى عدم تواجد إ (AGSالبشري )سرطان المعدة 
ً لتحتوي على مستقبالت ال  AGSو   mGEPخاليا  تم وبالتالي , PTH1R.والمعدلة وراثيا
في خاليا   ERK1/2شارات مسار ال إو   AGSفي خاليا ال   cAMPشارات مسار ال إتنشيط 
mGEP .  ا ال ذلك ت م قياس بقاء خاليو بعدmGEP   على قيد الحياة عند تعريض هذه الخاليا
ً للهرمون  ثبِت  (PTHrP(1-36المعدّلة وراثيا . لوحظ زيادة طفيفة في (PTHrP(7-34أو الم 
. كما تم (PTHrP(1-36ستخدام إساعة من   24قدرة الخاليا على البقاء على قيد الحياة بعد 
-LDLR, CaSR, ILعلى التعبير الجيني لعدد من الجينات  مثل  (PTHrP(1-36دراسة تأثير 
6, NHERF1, FGF23 تعد هذه الدراسة مهمة جدا في فهم دور المستقبل .PTH1R  الطبيعي
 لمرضى السرطان. الكيميائيفي المعدة و قد يكون لها تأثير كبير في تطبيقات العالج 
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1. Chapter 1: Introduction 
 
1.1 Overview 
Receptors in an organism are responsible for different cell responses. These 
communication elements are accountable for the cell to cell signal transmission over 
short or long distances across the body. Cells are equipped with unique protein 
structures located on their surface in order to read out the signals. Such signals lead to 
cell responses that can range from minute to major changes inside the cells. Receptors 
can be either activated by a specific signal to stimulate them, or can be inhibited by 
another signal. The stimulation or inhibition of the receptors can cause multiple 
signaling pathways to be activated; as such cells will be able to respond to this 
stimulus. 
Parathyroid hormone 1 receptor  (PTH1R) is a protein receptor found in 
multiple tissues of the body, dominantly in the kidney and bones [1,2], but its 
significant role in the stomach has not been fully identified [3]. PTH1R is a family B, 
G-protein receptor that contains three parts, an extracellular N terminal, seven 
transmembrane loops, and intracellular C terminal [2,4]. It has been reported that the 
main function of PTH1R is in bones and kidneys where it mediates extracellular Ca2+ 
homeostasis [3] and is important in bone growth and development [4]. In addition to 
these functions, PTH1R has been identified in the intestinal mucosa and in several 
carcinomas and adenocarcinomas [3,5].  
PTH1R has two ligands, parathyroid hormone like hormone (PTHLH) or also 
known as parathyroid hormone related protein (PTHrP), as well as the parathyroid 
hormone (PTH). PTHLH is a hormone that plays a key role in bone formation and 






muscles [7], and regulates various cellular events such as proliferation, differentiation 
and apoptosis [3]. However, it was also recognized and found to be highly expressed 
in hypercalcemia of malignancy, and many other types of cancers such as breast cancer 
[3,4,8]. Many studies were conducted and showed increased levels of PTHLH 
expression also in thyroid carcinomas [3,9], breast cancer [3], squamous cells tumors 
[3,8], and gastric cancers [3]. These studies highlighted the importance of PTHLH 
involvement in tumor proliferation and progression [3]. PTHLH is a complex hormone 
in which it can function as a paracrine, endocrine, and autocrine hormone [4]. It is well 
known that the PTHLH is expressed and found in the stomach [3]; however, very little 
research has been done on the expression of PTH1R in the stomach and its role in 
maintaining gastric homeostasis. The aim of this thesis is to investigate further the 
crucial function of PTH1R in gastric homeostasis. 
The focus of this project will be mainly on studying the PTH1R expression and 
role in the gastric homeostasis. This will apply further knowledge on the regulation of 
this receptor in gastric cancers. To further understand the structure of this project’s 
introduction, an overview of detailed stomach anatomy will be discussed first, 
followed by G- Protein Coupled Receptors (GPCRs) classification. Then, PTH1R with 
insights on its structure, ligands, and signaling pathways will be covered. Furthermore, 
PTH1R and its relation to health and multiple diseases associated with stomach, bones, 
breast cancer, and kidneys will be explained thoroughly followed by PTH1R mutations 
that cause diseases. Lastly, the importance of PTH1R in targeting specific genes and 







1.2 Stomach Anatomy 
The stomach of the mouse is composed of three distinct parts, forestomach, 
corpus, and the antrum as shown in Figure 1.1. The forestomach is connected to the 
esophagus, the middle compartment is the corpus, and the antral distal part which 
connects the stomach to the small intestine is called antrum. The forestomach is a non-
glandular tissue and is composed of stratified squamous epithelial cells. As for the 
corpus and antrum, they are glandular areas. Together, these two areas are responsible 
for secreting gastric mucins, hydrochloric acids, digestive enzymes, and hormones. 
 However, there are differences in the glands between the corpus and the 
antrum regions. The organization of these regions and glands is further illustrated in 
Figure 1.2. In the corpus, the glands are subdivided into four parts: pit, isthmus, neck, 
and base as illustrate in Figure 1.2a.  
The isthmus region which contains mainly the progenitor cells, and as a result, 
it was noted to contain the highest mitotic activity [10]. The progenitor stem cells also 
have the ability to differentiate into other cells which can migrate to the top (pit) of the 
gland or in the lower part of the gland (neck or base). The parietal cells found mainly 
in the isthmus and neck are the source for gastric acid regulation. They secrete gastric 
acid which it plays an important role in food digestion. They can also produce several 
growth factors. 
The pit, which is the top part of the gland, is an area that contains surface 
mucous cells that cover the lining of the stomach and secretes mucus to protect the 
stomach from strong acids and enzymes.  
Below the isthmus region is the neck region which contains migrated parietal 
cells from isthmus, neck region also contains mucous neck cells, and 






stimulate parietal cells to secrete gastric acid. Lastly, the base region located at the 
very bottom of the gland, containing zymogenic cells which secrete pepsinogen. It is 
important to note that the origin of all these cells comes from gastric epithelial 
progenitor cells [11-13].  
Moreover, the antrum gastric glands consist of surface mucous cells, 
progenitor cells, deep mucous cells, G cells which are endocrine cells secreting gastrin, 
and Lgr5+ stem cells as shown in details in Figure 1.2b [11,14,15]. The antrum gland 
contains highly proliferative regions below the pit region [10]. The gastric stem cells 
are responsible for maintaining the epithelial homeostasis inside the gland, due to their 















Figure 1.1: The mouse stomach anatomy 
 
The mouse stomach is divided into three regions: forestomach, corpus and antrum. The esophagus 
connects to the forestomach, while the small intestine connects to the bottom part of the stomach called 











Figure 1.2: Diagram of a gastric gland from corpus (a), and antrum (b) 
The corpus gastric gland is further divided into four regions; pit, isthmus, neck, and base. The antral 











1.3 G- Protein Coupled Receptors (GPCRs) 
GPCRs are the largest proteins in mammals and are categorized into six classes 
according to their structural and functional similarities. The six classes are; Class A, 
Class B, Class C, Class D, Class E, and Class F [16]. Table 1.1 lists the different 
classes, their names, and their biological functions and examples of each class. Class 
A named rhodopsin-like which is the largest group among the GPCRs. Class B named 
secretin-receptor family, which are regulated by peptide hormones. The Class B 
consists of glucagon receptors, parathyroid hormone receptor, and secretin receptors. 
Class C includes glutamate receptors and other receptors with similar structure. Class 
D, E, and F are important in stimulating multiple signaling pathways and regulate the 
activity of many genes [17].  
GPCRs share a similar overall structure in which they contain an extracellular 
N terminal, seven hydrophobic transmembrane loops, and intracellular C terminal as 
shown in Figure 1.3. The N terminal is categorized as a site for ligand binding, while 
the seven transmembrane portions consist of alpha helices which alternate within the 
lipid bilayer membrane. The intracellular C terminal is bound to G-proteins inside the 
cell.  
In the last three decades, GPCRs have been of growing interest due to their 
powerful actions in several biological events and pharmaceutical drug discoveries. 
Previous studies highlight the importance of GPCRs as biomarkers for early cancer 
diagnosis [16]. This illustrates the importance of GPCRs signaling target in drug 
discoveries, cancer treatments, cellular regulation and signal transduction.  
The mechanism of action starts when the ligand binds to the receptor at a 
specific active site, this will cause the G-proteins to be activated and induce a 






reactions within the cell. However, the active site in which the ligand binds to the 
receptor plays a critical role into which receptor signaling pathway to activate [17].  
Upon the activation of GPCR, one of the three subtypes of heterotrimeric G-
proteins located inside the cell will be activated, the three subunits are; Gα, Gβ, and 
Gγ as illustrated in Figure 1.4. These three subunits can further be classified into 
multiple subfamilies, for example Gα is additionally categorized as Gαs, Gαi, Gαq, and 
Gα12/13. These subfamilies will cause a cascade of further downstream protein 
activations and will therefore trigger a cellular response according to the ligands 











































Class type Functions Examples 
Class A   (Rhodopsin-like) -Important in extracellular 
signals.  








Class B   (Secretin 
receptor family) 
-Activate adenylyl cyclase  










Class C  (Metabotropic 
glutamate/ 
pheromone) 
-Unique ligand recognition 
sites 
-Calcium sensing receptors 





- γ-aminobutyric acidB 
receptors (GABAB) 
- Ca2+- sensing 
receptors (CaSR) [20]. 
Class D   (Fungal mating 
pheromone 
receptors) 
-Involved in the response to 
mating factors on the cell 
membrane[21]. 
-  Pheromone a factor 
receptor Ste2, Ste3 
[21]. 
 
Class E   (Cyclic AMP 
receptors) 
-Important in regulating  
developmental 
genes.[22,23]. 
- cAMP receptor 
subtype ( CAR1, 
CAR2, CAR3)[22,23]. 
Class F  (Frizzled/ 
Smoothened) 
-Important in  cell polarity, 
embryonic development, 
formation of neural 
synapses, and cell 
proliferation [24]. 
-  Frizzled receptors 










1.4 Parathyroid Hormone 1 Receptor (PTH1R) 
PTH1R has been categorized as a GPCR which was firstly discovered in 1991 
in COS-7 kidney fibroblast like cells [26].  It was detected to be around 80kD in size 
and has two ligands PTH and PTHLH. Both of these ligands can bind to PTH1R at 
different sites and at different affinities which can activate different GPCR pathways. 
PTH1R was classified to be Class B of GPCR due to its high structural similarity to 
secretin and glucagon hormone family [3].  
Its expression was mostly studied in bones and kidneys due to its important 
role in regulating calcium ion homeostasis in the blood through activation of adenylate 
cyclase and phospholipase C (PLC). However, PTH1R is also expressed in multiple 
other tissues and organs including adrenal glands, placenta, spleen and adipose tissue 
[3]. 
 It has been recorded that the genomic location of PTH1R is 3p21.31 in human. 
In other terms, it is located on chromosome 3, region 2, band 1, and sub band 31, with 
20 exon count. PTH1R mRNA codes for 593 amino acids in human as shown in Figure 
1.3, and 591 amino acids for mouse. It is located in chromosome 9 with 21 exon count 
in mouse. 
Defects and mutations in this receptor can cause Jansen’s Metaphyseal 
Chondrodysplasia (JMC) in which bones of the arms and legs tend to develop and 
grow abnormally with unusual cartilage and bone formation [2]. Recent studies also 
show PTH1R mutations can cause failure of tooth eruption in some human patients 
[27]. Defects by PTH1R will be further explained in more details in another section 
later in chapter 1 under the title (PTH1R Mutations). However, very little studies 
consider studying PTH1R in the gastric system, therefore its role and importance in 






1.4.1 PTH1R Structure 
Structurally, PTH1R consists of extracellular N terminal, 7 transmembrane 
domains, and an intracellular C terminal. As the rest of class B family, PTH1R shares 
a sequence homology with other related receptors in this group such as secretin and 
glucagon [6]. This identifies that these receptors all share some similarities within their 
modes of action and signaling [6].  
PTH1R is a receptor that allows for PTH (84 aa) and PTHLH (141 aa) to bind 
to it [28]. However, both molecules bind at different affinity and in different regions 
of the receptor [28]. On the other hand, PTH1R can be fully activated when small 
portions of the ligands bind to it, as such it does not require the full length of the ligand 
to completely bind to it [28]. An example is PTH (1-34) which is considered to be an 
agonist. It can bind to PTH1R from the N terminal and thus activating the receptor 
through Gαs pathway. PTH (1-34) was reported to bind at higher affinity resulting in 
prolonged activation and a longer lasting cAMP response of the receptor. Unlike 
PTHrP (1-36), which is another agonist, but it was reported to bind at a lower affinity 
to the receptor, however, it still activated Gαs pathway  [28]. To block the activation 
of PTH1R, a peptide used is PTH (7-34) which has been identified to be an antagonist 
that inhibits the action of the receptor [28]. 
Even though the amino acid sequence of PTH1R is identified as illustrated in 
Figure 1.3, yet the 3-D protein structure has not been fully established according to 
protein data bank (PDB). However, what make PTH1R similar in structure to its other 
counterparts in Class B GPCRs is its four pairs of extracellular cysteine (C) specific 
amino acids illustrated in Figure 1.3  [29]. These residues can form disulfide bond 






to maintain its structure and function. Other residues also play an important role in 
activating different signaling pathways, for example; Lys388 is important in Gαs 
signaling [29]. 
In the PTH1R intracellular C terminal, a nuclear localization sequence (NLS) 
is present, which highlights the regulation of PTH1R localization in the nucleus [30]. 
Although the transport of GPCRs from the cell membrane into the cell by endocytosis 
is well known, the knowledge of transporting GPCRs into the nucleus is relatively 
new.  
PTH1R was the third GPCR found to indeed translocate to the nucleus of the 
cell, which created a new range of studies regarding this phenomena [31]. Studies 
demonstrated that PTH1R nuclear import is actually possible [31]. Other studies 
confirmed PTH1R nuclear localization in rat liver, kidney, gut, ovary, and uterus [30].  
The nuclear localization sequence of PTH1R was identified, which was 
reported in the cytoplasmic domain amino acids 471 – 488 of the receptor shown in 
Figure 1.3 [30]. It was in fact well documented in another study that PTH1R 
translocate to the nucleus when mouse osteoblast-like cells MC3T3-E1 are serum 
starved. However, in normal cell culture conditions PTH1R can be found both in 
cytoplasm and nucleus [31]. They further studied the mechanism of such action, and 
noted that treating the cells with PTH peptide induce PTH1R cytoplasmic localization. 
To aid in this mechanism, they reported a relation between Importin α and β, both of 
these transport regulatory proteins aid in the translocation of PTH1R to the nucleus. 
The Importin protein will interact with the nuclear localization sequence NLS found 
in the receptor, this will further cause the translocation of the complex into the nucleus. 






cytoplasm, chromosomal region maintenance 1 CRM1 protein is involved, this process 
is named as nuclear export [31].  
The importance of this shuttling can regulate various cellular process, gene 
expression and proliferation [31]. However, other studies linked this translocation of 
the receptor to happen during DNA synthesis and mitosis. This highlighted the 




Figure 1.3: Human PTH1R structure 
 
Human PTH1R Amino Acid sequence organization. The composition of different parts and regions of 
PTH1R, including N-terminal, seven trans-membrane loops, and C- terminal. Important sequence sites 
are: Nuclear localization sequence 471 – 488 highlighted in blue, four pairs of Cysteine highlighted in 








Parathyroid hormone (PTH) is secreted by the parathyroid gland which are four 
tiny glands found in the neck. PTH plays a crucial role in maintaining and regulating 
calcium ion homeostasis in the blood. When calcium ions in the blood decrease, this 
causes the PTH to stimulate bone cells, specifically osteoclasts which help in breaking 
down bones to release more calcium in the blood. In other words, PTH can raise 
calcium levels by increasing bone resorption which is breaking down of bone tissues 
to produce more calcium, as such, this will decrease renal excretion of calcium and 
will stimulate Vitamin D to absorb calcium from the intestine through its receptor 
VDR [32].  
PTH can be regulated via two receptors PTH1R and PTH2R. However, PTH1R 
is deeply studied in bones and kidneys. Studies show that PTH treatments can increase 
bone mass when intermittently administered at low doses to patients with osteoporosis 
[28]. PTH role is very significant in bone regulation and maintain its homeostasis. PTH 
knockout mice showed substantial bone deformities and impaired bone formation 
[28,33]. 
Parathyroid hormone like hormone (PTHLH) was discovered as a cancer-
derived hormone which was reported in humoral hypercalcemia of malignancy 
(HHM). The term derives since 1941 [28] when it was first reported as a case study in 
a patient with high plasma calcium accompanying a non-parathyroid cancer. During 
that time, it was known that excess secretion of PTH causes hyperparathyroidism 
which results in high calcium in the blood. However, hypercalcemia was also noted in 
other cancers such as lung, breast, and kidney cancers. PTHLH was then identified 






which showed PTH like reactivity. By 1970, scientists concluded that the main cause 
of the hypercalcemia, and the tumor derived activity in some cancer patients did not 
originate from PTH itself, but from another hormone which very much resembles PTH, 
thus Parathyroid Hormone Like Hormone name appeared [34,35]. Recent studies to 
this date still support this idea, in which PTHLH is the reason for elevated calcium 
levels in blood, as well as tumor derived factor. Moreover, studies also show a similar 
N-terminal homology between PTH and PTHLH in the first 13 residues, which 
represents a possible agonist for both hormones to act on PTH1R [28]. 
Both of these ligands have been identified to be mediated through PTH1R. 
However, both can bind at different affinity and thus cause different signaling pathway 
to be triggered. 
Compared to PTH, PTHLH is thought to be produced by many tissues and it is 
expressed throughout the gastrointestinal tract [7]. However, very limited number of 
studies are conducted involving PTHLH expression in the stomach [36,37], and it 
regulatory receptor PTH1R signaling pathway in maintaining gastric homeostasis. 
1.4.3 Major PTH1R Signaling Pathways 
In the case of PTH1R which is categorized as a GPCR Class B, two ligands 
can activate this receptor, PTH and PTHLH. Both of these hormones can further 
activate different PTH1R G proteins. The four possible activations are: Gαs, Gαi, Gαq, 
and Gα12/13. Figure 1.4 illustrates the multiple types of PTH1R activations. However, 









cAMP signaling pathway 
The activation of the Gαs pathway will cause a different cascade of downstream 
reactions. Firstly, the activation of adenylyl cyclase (AC), which will generate cyclic 
adenosine monophosphate (cAMP). Secondly, cAMP will activate protein kinase A 
(PKA) which will regulate several cellular proteins, and target specific genes [6]. 
To fully activate PTH1R, two highly studied agonists can be used, PTH (1-34) 
and PTH (1-36). The N-terminal of these agonists is fully capable of activating the 
receptor. Some studies suggest that other agonists like PTH (1-31) can stimulate AC 
and PLC pathways, however it cannot internalize PTH1R [38]. On the other hand, PTH 
(7-34) acts as an antagonist which causes a blockage or inhibition of PTH1R. Other 
peptide activators or inhibitors exist to this day, but they can cause other signaling 
pathways in GPCR to be activated. This broad range of peptide activators highlight an 
important focus on the specific ligand-receptor binding, which is selective and can 
trigger targeted signaling pathways in different organs and cells.  
cAMP in the gastric system has important roles in regulating stomach 
homeostasis. Parietal cells found in the stomach are responsible in Gastric acid 
secretion. These cells contain vesicular tubular organelles that carry a proton pump 
H+/K+ ATPase which maintains H+ ion homeostasis in the stomach [39]. It has been 
reported that Histamine, gastrin, and acetylcholine act as gastric transmitters. 
Histamine is a regulatory hormone responsible to activate Histamine receptor 
2 (H2), this receptor is categorized as a GPCR which activates the Gαs signaling 
pathway [39]. This activation will initiate Adenylyl cyclase and protein kinase A 
which will cause the production of cAMP as a secondary messenger in the cell [40]. 
Acetylcholine and gastrin are also responsible in the induction of calcium ions. 






[39].  However, these parietal cell transmitters can be activated by different ligands 
and can be caused by different stimulus, whether it is increase in calcium ions or 
cAMP. 
Some studies claim that certain basal levels of cAMP are crucial for the parietal 
cells to be stimulated by calcium ions [40]. On the other hand, some studies show that 
calcium ions are also important for the parietal cells to be activated through cAMP 
pathways [40]. Studies demonstrate a cross talk between calcium ions and cAMP 
pathways in general; however more studies are yet to be conducted to verify their 
effects on gastric acid secretion [41].  
 
ERK1/2 signaling pathway 
One of the highly studied pathways is the phosphorylation of extracellular 
signal regulated kinase (ERK1/2). It can be activated by many extracellular signals 
such as growth factor and hormones, or it can be activated by GPCR Gα, Gβ, and Gγ. 
This pathway is significant in many cellular actions including PTH and PTHLH 
involvement in differentiation, proliferation, survival and calcium transport [42]. 
Activation of this pathway has been reported in many endocrine cells such as; 
osteoblasts, bone cells, and kidney cells [42]. Other studies illustrates that activation 
of ERK1/2 in stomach cancer cells KATO III through GPCRs induced proliferation 
[43]. Some studies even suggested using drugs to inhibit gastric cancer cells from 
proliferating via inhibition of ERK1/2 [44]. However, it would be interesting to find 
out if PTH1R in the stomach has a role in this activation. 
Some studies documented PTHLH amino terminal internalization into the cell 
after activating its receptor PTH1R [45]. Moreover, it has also been discovered that 






been localized in the nucleus of some skeletal cells in vivo, and its role was significant 
in regulating differentiation and apoptosis in vitro [45]. Some studies even proposed 
the endocytosis of PTH1R after the ligation with its ligand PTHLH.  
Studies investigated the possibility of actually whether or not PTH1R can be 
internalized from the cell membrane to the inside of the cell. The entire process of 
GPCR desensitization and resensitization is further explained in Figure 1.5. Briefly, 
when the ligand binds to the receptor, it will cause the phosphorylation and change in 
the conformation of the receptor. This mechanism can cause the uncoupling of Gα, 
Gβ, or Gγ subunit from the receptor, this in turn will cause β-arrestin to increase its 
affinity to the receptor, and will bind to the receptor causing desensitization. The 
receptor will further translocate inside the cell with β-arrestin, in which it can activate 
Extracellular signal Regulated Kinases ERK1/2 [38]. Furthermore, the receptor can 
either be broken down by lysosomes, or resensitized back to the cell membrane. This 
method is helpful in a way which will regulate the receptor activation, and thus prevent 
prolonged receptor activity and stimulation [38].  
Desensitization of GPCR PTH1R alpha group Gαs and Gαq by β-arrestin was 
documented in some studies [38,42]. In a study conducted in 2005, they used human 
embryonic kidney (HEK293) cells to investigate PTH1R trafficking and activation of 
extracellular signal regulated kinases ERK1/2 by stimulating the receptor with PTH 
(1-34) peptide [42]. Consequently, the agonist peptide PTH (1-34) was able to induce 
a rapid activation of ERK1/2 in the first five minutes of stimulation unlike in PTH (1-
36), in which they found no similar significant effects. They further proposed that PTH 
(1-34) agonist and PTH (7-34) antagonist were able to phosphorylate ERK1/2 and 
cause PTH1R internalization into the cell. However, PTH (7-34) antagonist promoted 






PTH1R can actually be internalized into the cell, using the aid of β-arrestin recruitment 
to the cell membrane to  desensitize the receptor [42].  
Another study conducted in 2004 [38], in which they removed a portion of 
PTH1R C terminal, and they reported that PTH1R was not able to get internalized into 
the cell. They concluded that PTH1R C terminal contain a sequence that is involved 
in receptor internalization [38].  
The activation of ERK1/2 has been studied intensively in bone marrow cells 
and kidney cells, and it is associated with differentiation, proliferation, and calcium 
transport. However, very little studies were conducted on stomach to test PTH1R 
trafficking into the cell and activating ERK1/2. 
 
PLC signaling pathway 
Another  pathway for PTH1R is Gαq which will activate phospholipase C 
(PLC) which will trigger downstream signaling involving inositol triphosphate (IP3) 
and protein kinase C (PKC) [29]. This pathway is further explained in Figure 1.4. 
For the purpose of this project, I will be focusing and studying the Gαs pathway 










Figure 1.4: GPCR signaling pathways 
 
GPCR multiple signaling pathways activations and secondary messengers involved in multiple downstream signaling. The focus of this project will be on Gαs and β-










Figure 1.5: GPCR endocytosis trafficking 
 
Detailed explanation of GPCR internalization into the cell by β-arrestin recruitment to the receptor. The diagram illustrates the desensitization and resensitization of 









1.5 PTH1R in Health and Diseases 
In this section PTH1R and its role in different organs and diseases such as in 
stomach, bone cancer, breast cancer, and kidneys will be discussed.  
1.5.1 PTH1R in Stomach 
There is limited number of studies available for PTH1R in the gastric system. 
In one family, a case study was conducted in which it linked a mutation of PTH1R and 
ATPase H+/K+ to loss of function in parietal cells which lead to gastric tumor, 
hypothyroidism and arthritis [47]. Another case study also identified PTHLH and 
PTH1R to be highly expressed and involved in gastric tumor and the metastasis of the 
tumor to other organs [48]. One study also mentioned the importance of PTH1R in 
relaxing gastrointestinal muscles [49]. It is important to note that PTH1R is not well 
studied in the gastric system and very limited information is available regarding this 
issue. As such, knowledge from other organs and researches will be important in 
studying the role of PTH1R in stomach. 
1.5.2 PTH1R in Bones 
Osteosarcoma (OS) is one of the most common cancer of bones [50]. It occurs 
mostly in children, and when diagnosed and localized, patients have a five years 
survival rate [50]. However, treatment for osteosarcoma is mainly administered drugs 
to control the proliferative cancer cells, or in other cases surgical resection. 
 PTH plays a major role in regulating bone cells and development of mature 
bones. It has been reported that PTH treatments increase bone mass. However, PTHLH 






Since both of these hormones can act on PTH1R, then this raise a potential on 
targeting this receptor to study its importance. It has been reported that intermittent 
PTH treatment can increase bone mass and inhibition of osteoblast apoptosis. PTH has 
also been reported to be used as a treatment for osteoporosis which enhances bone 
resorption [52]. However, long term and high doses of PTH can trigger and cause OS. 
This is further supported  in other studies [52]. In one study, knockdown of PTH1R 
inhibited proliferation and tumor growth inhibition and increased differentiation in 
vitro. It is important to note that the knockdown of PTH1R did not affect the viability 
of cells in this study, however, it was able to impair the invasion of cells [50]. Other 
studies showed overexpression of PTH1R increased proliferation in OS cells 
[33,50,54]. 
Other in vivo studies demonstrated the anabolic bone formation effect of 
intermittent low-dose PTH (1-34) treatment on bones [55,56].  However, continuous 
high-dose treatment of PTH showed increase in bone turnover, resorption, and 
hypercalcemia.  
Osteoporosis is defined as an imbalance between bone resorption by 
osteoclasts and bone formation by osteoblasts causing reduction in bone mineral 
density (BMD) [52]. PTH (1-34) and PTH (1-36) intermittent treatment have been 
established as an osteoporosis treatment to induce osteoblastic bone formation and 
increasing BMD [28,52,57]. It was also reported in 2002 that PTH (1-34) the first 
anabolic agent for treating osteoporosis in the United States [58]. However, due to the 
fact that PTH can activate multiple signaling pathways, and not precise exclusive 
anabolic actions, another analog PTHLH (1-34) has been recently approved in 2017 






1.5.3 PTH1R in Breast Cancer  
Breast cancer has been associated previously with skeletal metastases [59]. 
Some studies suggested a link between breast cancer and PTHLH and considered 
breast cancer mediation through PTHLH expression, especially since the identification 
of PTHLH in breast cancer in 1987 [59]. It is also important to note that elevated levels 
of PTHLH was reported in breast cancer patients and this induced tumor initiation, and 
progression, and cellular proliferation [60,58]. Another study reported silencing 
PTHLH in breast cancer cells affected over 200 genes expression tested by microarray 
analysis [60] . 
In another epidemiology study, in which an increase in breast cancer was 
associated with type 2 diabetes, they investigated the role of PTH1R on apoptosis of 
breast cancer cells exposed to high levels of glucose [61]. It was reported that PTH1R 
expression increased in mice with diabetes. Furthermore, they also reported an 
increase in PTH1R in patients with breast cancer and diabetes. Additionally, they 
found that silencing PTH1R inhibited cell proliferation and promoted cell apoptosis 
induced by high levels of glucose [61].  
Moreover, breast cancer patients have reported severe bone pain and 
hypercalcemia, which eventually lead to skeletal metastasis [58,60]. It is known that 
PTH1R regulate calcium homeostasis along with extracellular calcium-sensing 
receptor (CaSR). This highlights the important cross talk between breast cancer and 
bone cells by PTH1R. It was also proposed a future targeting of PTH1R and CaSR in 
order to control breast cancer tumor growth and inhibition on cell proliferation as well 






1.5.4 PTH1R in Kidneys 
PTH1R has been reported to be highly expressed in the kidney for its effective 
role in maintaining its development maturation, structure and function by regulating 
calcium ions in the blood [62]. 
Calcium homeostasis in the blood plays a crucial role in kidneys. When the 
calcium level is low, this stimulates the chief cells in the parathyroid glands, and thus 
PTH secretion will increase and will allow it to bind to PTH1R. Furthermore, this will 
help in renal tubular reabsorption of calcium and in fact will increase Vitamin D 
synthesis to induce calcium absorption in the gut and hence facilitate osteoclast bone 
resorption to secrete calcium ions. In this mechanism, the body will be able to maintain 
systemic mineral ion homeostasis and calcium levels in the blood [63].  
In a diabetic kidney, it was shown that PTHLH and PTH1R are overexpressed. 
It was reported that treating renal kidney cells with high glucose will increase the 
expression of PTHLH and PTH1R [1]. 
In one study on human embryonic kidney cells, they activated PTH1R and 
tested the apoptotic signaling pathways effects. They reported that PTH1R activated 
mitochondrial apoptosis pathways, and the overexpression of PTH1R led to an 
imbalance in the mitochondrial membrane. This highlighted the importance of PTH1R 
in apoptosis of kidney cells [64]. 
PTHLH and PTH1R have been under the investigation for their upregulation 
in renal injuries [65]. This, in fact, will cause the development of renal hypertrophy 






1.6 PTH1R Mutations 
Mutations in PTH1R have been reported to be associated with multiple 
diseases such as; Jansen type metaphyseal chondrodysplasia, primary failure of tooth 
eruption, and Eiken skeletal dysplasia according to online Mendelian inheritance in 
man database (OMIM).  
Jansen type metaphyseal chondrodysplasia is a mutation categorized as a 
heterozygous missense mutation in PTH1R gene in which it is categorized by short 
limbed dwarfism caused by impaired growth plates of bones and mineral ion 
imbalance. The mutation is thought to be in amino acids residue 223 in which Histidine 
was replaced with Arginine [2,66,67].  
Primary failure of tooth eruption is a heterozygous splice site or nonsense 
mutation in PTH1R [62]. This disease is categorized as growth deficiency in teeth [27]. 
The mutation is reported in multiple places, for example it is noted in amino acid 
position 155, in which Glutamate undergoes Termination [68]. 
Eiken skeletal dysplasia is another bone disorder is which abnormal modeling 
of the bones and cartilage and severely delayed ossification is found in the hands, feet, 
and pelvis [48]. It is reported as a homozygous nonsense mutation in the c-terminal of 
PTH1R gene. Moreover, the specific truncation of the mutation on Arginine 485 to 
Termination [69]. This disorder is very similar to Jansen type metaphyseal 
chondrodysplasia, however, an important finding in one study in which they compared 
both disorders found that there was significant increase in vitamin D in patients with 
Jansen type metaphyseal chondrodysplasia [70] compared to Eiken patients [69]. 






1.7 PTH1R Target Genes 
PTH1R is involved in several cross talks with other receptors. The activation 
or inhibition of PTH1R is involved in multiple regulatory actions downstream in the 
genomic pathway. Examples of some PTH1R direct and indirect target genes include: 
calcium sensing receptor (CaSR), fibroblast growth factor 23 (FGF23), interleukin-6 
(IL-6), low density lipoprotein receptor (LDLR), and Na+/H+ exchanger regulatory 
factor 1 (NHERF1) as shown in Table 1.2. 
The extracellular calcium sensing receptor, also known as CaSR, is a family C 
GPCR. Its major role is to detect minor alterations in blood calcium levels, and in turn 
indirectly induce PTH secretion and urinary calcium excretion [71]. Regulating 
calcium is a very complex process that involves many components to maintain its 
homeostasis. When calcium levels in the blood drops, this is sensed by CaSR, which 
in turn stimulates the parathyroid gland to secret PTH. This hormone will stimulate 
PTH1R to induce bone resorption which breaks down the bones to release calcium 
ions into the blood. Furthermore, PTH will also enhance Vitamin D synthesis in the 
renal system which will aid the intestines in calcium absorption [71-74]. This 
regulation mediates calcium homeostasis, and as such leads to feedback inhibition of 
PTH secretion. 
The cross talk between CaSR and PTH1R has been reported previously in 
breast cancer [75]. PTHLH has been involved in breast cancer tumor progression and 
metastasis to the bones. It is reported that CaSR contributes to breast cancer cell 
proliferation [58].  
CaSR was also found to be expressed in gastric tissues in parietal cells [76], 
and in gastric cancer. Studies illustrate the upregulation of CaSR expression [77]. For 






it has been reported that calcium activates CaSR and causes gastric cancer growth, 
unlike the case in colorectal and pancreatic cancer, in which calcium suppressed the 
tumor growth [77]. 
FGF23 has been reported to be induced and upregulated directly by PTH in 
bones when there is high phosphate and vitamin D levels in the blood [78,79]. Other 
studies demonstrated that PTH (1-34) treatment in vitro to osteocyte-like cells resulted 
in increased levels of FGF23 in the first initial 2 hrs, but the levels returned back to 
normal by 4 hrs. [80] Another study conducted in which PTH1R was deleted from 
kidney in mice showed significant increase in FGF23 and challenging  the mice with 
PTH (1-34) caused an upregulation of FGF23 [81]. However, removal of PTH1R from 
bones downregulated FGF23 levels [81].  
 IL-6 is a pro-inflammatory cytokine studied in cases of hyperparathyroidism 
in which it is indirectly upregulated when PTHLH stimulates PTH1R in cancer cells 
[83]. IL-6 has been studies in patients with gastric cancer, and research shows that IL-
6 is involved in gastric cancer spread of tumor and invasion [84,85]. Another study 
related PTH treatment in osteoblastic cells and results showed an induction in IL-6 
[5,86,87]. 
LDLR is responsible for the uptake of cholesterol and is very important in 
maintaining plasma levels of lipoprotein. PTH is shown to induce LDLR when it binds 
to PTH1R [88]. Very limited number of research that related PTH1R and LDLR 
especially in gastric system. 
 NHERF1 consists of two domains, PDZ and carboxyl-terminal ezrin binding 
domain (EB). NHERF1 acts as cytoplasmic adaptor protein and has the ability to bind 
and form different complexes with other molecules causing trafficking [89].  It is also 






important in cellular localization [91,92]. NHERF1 levels were detected at high 
amount in nucleus of cancer cells, thus altering some signaling pathways and second 
messengers [92]. NHERF1 has been documented to directly interact with PTH1R and 
internalize with it when it is desensitized and cause endocytosis of the receptor into 
the cell [92,93,95].   
1.8 Thesis Objectives and Hypothesis 
Since there are limited studies focusing on PTH1R importance in the stomach, 
this project will investigate this issue further. This study is important as it will explore 
the expression and function of PTH1R in the stomach, and how this receptor signaling 
affects gastric homeostasis. This work might also set some impacts in the development 
of new therapeutic agents for gastric cancers. 
There are two goals of my master thesis; the first is to find the expression and 
cellular localization of PTH1R in the mouse stomach, second, is to study the role of 
PTH1R signaling in gastric epithelial homeostasis in vitro. 
Moreover, I am hypothesizing that PTH1R is expressed in the mouse stomach 
and its signaling is required for gastric epithelial homeostasis. To support my 
hypothesis, different experiments will be conducted involving PCR, Immunostaining, 

















Table 1.2: Some PTH1R target genes 
 
Target Gene Function Reference 
CaSR Calcium Sensing 
Receptor 
To detect minor 
alterations in blood 
calcium levels. 
[71,72] 
FGF23 Fibroblast Growth 
Factor 23 
Is a bone derived 
hormone regulating 
vitamin D activation in 
kidney. 
[78,79] 
IL-6 Interleukin-6 A pro-inflammatory 
cytokine which is 
studied in cases of 
hyperparathyroidism. 
[83] 
LDLR Low Density 
Lipoprotein Receptor 
Responsible for the 
uptake of cholesterol 
and is very important in 
maintaining plasma 
levels of lipoprotein. 
[88] 
NHERF1 Na+/H+ Exchanger 
Regulatory Factor 1 
Acts as cytoplasmic 
adaptor protein and has 
the ability to bind and 
form different 










2. Chapter 2: Methods 
 
2.1 Animals and Cells 
C57BL/6J three month old mice (n=3) (2 males, 1 female) were kept in Specific 
Pathogen Free (SPF) facility located in the Faculty of Medicine and Health Sciences 
in United Arab Emirates University (UAEU). The mice were fed normal diet 
D10012Gi, Research Diet for three months, and then starved over night before 
dissection. Stomach tissue was collected to conduct IHC and Real-Time PCR analysis. 
Cells used were Gastric Adenocarcinoma (AGS),  stomach cancer cells NCI-
N87, cervical cancer cells HeLa, cells obtained from American Type Culture 
Collection (ATCC), Human Embryonic Kidney (HEK293) generously provided by Dr. 
Ayoub (UAEU), and Mouse Gastric Epithelium Progenitor cells (mGEP) which are 
cells derived from FVB/N transgenic mouse expressing an oncogene, the simian virus 
(SV40) large T antigen gene  [96] were generously provided by Dr. Karam (UAEU). 
mGEP and AGS cells were cultured in RPMI-1640 medium (Sigma), and HEK293 
cells were cultured in DMEM medium (Gibco). Both mediums were supplemented 
with 10% Fetal Bovine Serum (FBS) and 100 U/ml/50μg/ml Penicillin-Streptomycin 
(Life Technologies). Cells were grown in a humidified Binder incubator at 37°C in 5% 
CO2 atmosphere. 
2.2 RNA Isolation and Reverse-Transcription PCR  
For the mice stomach, total RNA was isolated from different stomach regions 
(forestomach, corpus, and antrum) using RNeasy Mini Kit (Qiagen). Normal human 
stomach total RNA sample was purchased from Origene. RNA isolation for the cells 






DNase Kit (Qiagen). cDNA was then synthesized using iScript cDNA synthesis Kit 
(Bio-Rad) by using 1μg of RNA as recommended by the manufacturer. 
RT-PCR was used to test the expression of PTH1R and other genes in vivo and 
in vitro by using GoTaq Flexi DNA Polymerase kit (Promega). Primers and product 
size used are listed in Table 2.1. 
PCR product was then separated by gel electrophoresis using 1.5% agarose gel 
with Ethidium Bromide and bands were visualized using Gel Doc EZ Imager (bio-
rad). 
2.3 Histological analysis 
Mouse gastric tissue collected was fixed by Bouin Fixative for 24 hrs., then 
washed with 70% ethanol and processed by using 5μm sections. Slides were then 
stained with the appropriate antibody and imaged using Olympus microscope IX83.  
2.3.1 Immunohistochemistry (IHC) 
Immuno-peroxidase staining was used by heat induced antigen retrieval, and 
all sections were pretreated with 3% H2O2 to inhibit endogenous peroxidase activity. 
Sections were incubated with 1% Bovine Serum Albumin for one hr. Followed by 
overnight 4°C staining with Rabbit Polyclonal to anti Parathyroid Hormone Receptor 
1 (ab75150, abcam, dilution 1:100). Then, biotin-SP conjugated goat anti-rabbit was 
used and incubated for one hr. at room temperature. Followed by PBS wash, slides 
were then incubated with Extravidin-Peroxidase at dilution 1:1000 in blocking reagent 
at room temperature. Further PBS washing, and then DAB:UREA (1:1) was added for 
six minutes and washed with distilled water and counterstained with hematoxylin. 






2.3.2 Immunocytochemistry (ICC) 
mGEP and AGS cells were stained and imaged using Olympus microscope 
IX83. Cells were seeded on 6 well plate with coverslip inserted at a density of 200,000 
cells/well using RPMI-1640 Full medium. Cells were then transfected and left till 70% 
confluent. Cells were rinsed with PBS and fixed with 3% Formaldehyde in 1xPBS for 
20 minutes at room temperature, followed by PBS rinsing. Cells were then 
permeabilized using 0.1% triton x 100 PBS for 15 minutes at room temperature, 
following with PBS rinsing. Cells were blocked with 1% Bovine Serum Albumin 
(BSA) for one hr. at room temperature. Cells were incubated with primary antibody 
Rabbit Polyclonal to anti Parathyroid Hormone Receptor 1 (ab75150, abcam, dilution 
1:50) in blocking reagent overnight. Next day, cells were rinsed by PBS containing 
1% goat serum for 10 minutes and incubated with secondary antibody goat anti-rabbit 
IgG H&L Cy3 (ab6939) for one hr. at room temperature followed by PBS washing. 
Finally, DAPI with mounting media was placed on the microscopic slide and the 
coverslip was placed on top. Negative controls were used in the absence of primary 
antibody. 
2.4 Transformation and Transfection 
Two PTH1R dry plasmids were purchased from (cDNA Resource Center) 
weighing 5000ng, clone ID PTHR100000 and PTHR10TN00. Autoclaved water (50 
μL) was added to each tube, 100ng/μL concentrations of the plasmids were used 
further for transformation. Plasmids were placed in 37°C water bath for 10 minutes.  
Bacteria cells were used NEB 5-alpha competent E. coli. Plasmids and bacteria 
were mixed and placed 10 minutes on ice, followed by 45 seconds at 42°C in heating 






plasmid and incubated for one hr. at 37°C shaking incubator. Next, tubes containing 
plasmids and bacteria were centrifuged at 5000 rpm for five minutes. Supernatant was 
removed, and the pellet was re-suspended in LB media. Mixture was plated on Agar 
petri-dish containing Soya, Bacteriological Agar, Kanamycin, and Ampicillin and left 
to dry for 10 minutes. Petri-dishes were then incubated at 37°C inverted for 24 hrs. 
until bacteria colonies are visible. 
Next, 200 ml SOC LB media is prepared with 200μL of ampicillin and placed 
in a flask. One colony from the grown bacteria is taken using a tip and placed inside 
the flask and incubated at 37°C overnight in shaking incubator. Next day, samples 
were centrifuged at 6000g for 15 minutes. Supernatant was discarded, and the pellet 
was stored in -20°C. 
For plasmid extraction and purification Qiagen Plasmid Maxi Kit was used as 
recommended by the manufacturer. Concentrations of the plasmids were further 
checked by NanoDrop 2000 from Thermo Scientific. Plasmids were diluted to make 
the concentration up to 1μg/μl. Gel electrophoresis was used to check DNA integrity 
using 1% gel. 
For transfection, lipofectamin 2000 from (Invitrogen) and Opti-MEM reduced 
serum media from (Gibco) were used. When transfecting 6 well plate, cells need to be 
seeded until 70% confluent. Next, two complexes were made. First, 12μg of plasmid 
is diluted in 1,200μL OpTi-MEM, and second is 50μL lipofectamin is diluted in 
1,200μL Opti-MEM. Solutions are incubated at room temperature for 5 minutes, then 
mixed together and incubated for 30 minutes at room temperature. Old media is 
discarded from the 6-well plate cells and new fresh media is added with the 






treated with different doses of agonist PTHrp (1-36) and antagonist PTHrp (7-34) 
(Bachem). 
2.5 Western Blot 
mGEP cells were cultured in 6 well plate at a density of 200,000 cells/well 
using RPMI-1640 medium supplemented with 10% FBS and 100U/ml/50μg/ml 
penicillin-streptomycin. Cells were transfected with PTH1R plasmid 2μg/well for 24 
hrs, and then starved overnight for 12 hrs before introducing the agonist PTHrP (1-36) 
at 0.01μM and 0.1μM concentrations for 5 minutes. Cells were lysed using RIPA 
buffer containing phosphatase and protease inhibitors. Cells were incubated for one 
hr. at 4°C and then scrapped and centrifuged and the supernatant containing the protein 
was collected.  
Resolving/separating gel 10% and 5% stacking gels, containing H2O, 40% 
Acrylamide, 1.5M Tris (pH 8.8), 10% sodium dodecyl sulfate (SDS), 10% Ammonium 
Persulfate (APS), and Tetramethylethylenediamine (TEMED) were prepared. 
Proteins were then transferred from the gel to the Polyvinylidene difluoride 
(PVDF) membrane for 90 minutes at 100 Volts, followed by blocking using 5% 
skimmed milk. ERK1/2 and pERK1/2 antibody from (cell signaling technology) were 
used at dilutions 1:1000 in 5% BSA, and 1:2000 in 5% skimmed milk respectively. 
Membranes were incubated at 4°C overnight. Membranes were then incubated with 
cell signaling technology secondary antibody anti-rabbit for ERK1/2 and anti-mouse 
for pERK1/2 for 45 minutes. SuperSignal™ ELISA Femto Substrate from 
(ThermoFisher Scientific) was used as substrate. Bands were detected using BioRad 






2.6 cAMP Measurement 
cAMP measurement was done by two different kits. cAMP-Glo Max Assay 
obtained from Promega, and cAMP-Gs dynamic kit from CisBio.  
For the Promega-cAMP, kit, AGS cells were seeded and transfected in 96 well 
plate. Preparation of the reagents including induction buffer, detection buffer and 
kinase reagent were prepared according to the manufacturer’s instructions. Reagents 
were added to the treated cells, and plate was read using plate reader- Glomax from 
Promega.   
Cisbio-cAMP kit was also used to detect levels of cAMP after treating the cells 
with agonist. Cells were seeded and transfected, stimulation buffer, Anti-cAMP 
cryptate (donor) was added along with cAMP d2 (acceptor) and incubated for 25 
minutes at 37°C before reading the plate using TriStar2 S LB 942 from Berthold 
Technologies. All reagents were prepared according the manufacturer’s instructions. 
2.7 Cell Morphology Analysis 
mGEP cells were cultured in 6 well plate at a density of 200,000 cells/well 
using RPMI-1640 medium supplemented with 10% FBS and 100U/ml/50μg/ml 
penicillin-streptomycin. Cells were transfected with PTH1R plasmid 2ug/well for 24 
hrs., and then starved overnight for 12 hrs. before introducing the treatment at different 
concentration. Agonist PTHrP (1-36) and antagonist PTHrP (7-34) concentrations 
were 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2.5, 5, and 10 μM. Treated cells morphological 
changes were monitored at different times (6, 12, 24, and 48 hrs). Imaging was done 






2.7.1 Cell Cytotoxicity 
mGEP cells were seeded in triplicate in 96-well plate at a density of 5,000 
cells/well using regular RPMI-1640 medium supplemented with 10% FBS and 
100U/ml/50μg/ml penicillin-streptomycin. Cells were transfected with PTH1R 
plasmid for 24 hrs., cells were then starved overnight for 12 hrs. with serum free media. 
Cells were then treated with different concentration of agonist PTHrP (1-36) and 
antagonist PTHrP (7-34). Concentrations were 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2.5, 5, and 
10 μM. Reading were taken after 24 hrs, and 48 hrs. Controls used were Un-transfected 
cells and transfected cells not treated. The effect of the drugs on cell viability was 
determined using Cell Cytotoxicity Kit (Abcam 112118) according to the 
manufacturer’s instructions. Experiment was conducted four times. 
2.8 Quantitative Real-Time PCR 
QRT-PCR QuantiStudio 5 (Applied Biosystems(ABI))  was used to determine 
the effect of transfected mGEP cells treated with (1μM) PTHrP (1-36) on different 
target genes. SYBR green dye was used for quantification of cDNA. Table 2.2 shows 
the different target gene primers used for the reaction. PCR reaction volume of 20μl 
were used for 40 amplification cycles. Samples were loaded in triplicates and values 
were calculated using ΔΔCT Method and normalized to GAPDH gene expression 
level. 
2.9 Statistical Analysis  
Statistical analysis was conducted using Graphpad Prism 7.0.3 in order to 
calculate the significance and draw the graphs. Data analyzed via one-way or two-way 






multiple comparisons post-test. Significance was indicated using asterisks *p<0.05, 





























3. Chapter 3: Results 
3.1 PTH1R is Expressed in Human Stomach and Cell Lines 
RNA analysis for normal human stomach, and multiple human cell lines such 
as HeLa and HEK293 showed positive gene expression of PTH1R using PCR.  
However, AGS, and NCI-N87 which are two cancer stomach cell lines did not 


















Figure 3.1: PTH1R mRNA is expressed in human stomach and other human cell 
lines 
 
RT-PCR detected expression of PTH1R in normal human stomach, HeLa cells which are derived from 
cervical cancer, HEK293 which are Human Embryonic Kidney cells. No expression for PTH1R was 



















3.2 PTH1R is Expressed in Normal Mouse Gastric Epithelial Tissues 
RNA analysis using normal mouse stomach three distinct regions 
(forestomach, corpus, and antrum) showed positive gene expression of PTH1R. 
However, mGEP cells did not show any expression using PCR Figure 3.2 (A). 
To further confirm this result at the protein level, IHC was conducted on the 
corpus gland of wild type mouse. Staining results showed a positive expression of 
PTH1R in the base of the corpus gland. Kidney tissue was used as positive control. 





















Figure 3.2: PTH1R gene is expressed in gastric tissue of wild type mouse 
 
(A) RT-PCR detected expression of PTH1R gene in gastric epithelial tissue of C57BL/6J wild type mice 
(n=3) at the age of 3 months. The tissues were collected from different regions of the stomach tissue 




















Figure 3.3: Immunohistochemical analysis of the corpus gastric gland showing 
PTH1R expression 
 
Wild type C57BL/6J mice (n=3), (age 3 months) were sacrificed and the collection of stomach and 
kidney was done. (A and B) represent sections in mouse Corpus tissue. (C and D) represent mouse 
kidney sections. The staining for PTH1R was conducted using Rabbit polyclonal to anti-Parathyroid 







3.3 The Transfection of mGEP and AGS Cell Lines with PTH1R Plasmid 
To overcome the limitation that PTH1R was not expressed in stomach cell lines 
mGEP and AGS. Transient transfection of PTH1R plasmid was conducted to force an 
expression of the target receptor PTH1R by the cells. To confirm that PTH1R plasmid 
was successfully transfected into mGEP (Figure 3.4) and AGS cells (Figure 3.5), 
Immunocytochemistry was conducted. It was noted the cellular localization of PTH1R 
























Figure 3.4: mGEP cells expressing PTH1R after successful transfection 
 
(A, B, C) represents un-transfected mGEP. (D, E, F) represents PTH1R transfected in mGEP. (G, H, I) 
represents mouse kidney as the control. Staining was done using Rabbit Polyclonal to anti Parathyroid 






































Figure 3.5: AGS cells expressing PTH1R after transfection 
 
(A, B, C) represents un-transfected AGS cells. (D, E, F) represents PTH1R transfected in AGS. (G, H, 
I) represents mouse kidney section as positive control. Staining was done using Rabbit Polyclonal to 
anti Parathyroid Hormone Receptor 1 (ab75150, abcam, dilution 1:100). Scale bar (A to F) is 100μm. 

























3.4 The Induction of cAMP in Transfected AGS Treated with PTH1R Agonist 
Suggests Receptor Activation via Gαs Signaling Pathway 
To study the effect of PTH1R agonist PTHrP (1-36) in gastric cells; AGS cells 
were transfected with PTH1R and treated with 1μM of its agonist PTHrP (1-36). 
Forskolin was used as a positive control stimulator for cAMP production. Results 
support the activation of Gαs signaling pathway by PTH1R as the accumulation of 




Figure 3.6: cAMP induction in PTH1R transfected AGS cells 
 
AGS cells were transfected and treated with PTHrP (1-36) agonist 1μM. Forskolin 10μM was used to 
stimulate the production of cAMP as a positive control. Data represents positive stimulation of cAMP 
after treating transfected AGS with PTHrP agonist. Two-way ANOVA test was used for data analysis. 




















































B a s a l
F o rs k o lin  (1 0  u M )
P T H rP  (1 -3 6 )  (1  u M )
Dunnett's multiple comparisons test
  AGS:Basal vs. AGS:Forskolin (10 uM)
  AGS:Basal vs. AGS:PTHrP(1-36) (1uM)
  AGS:Basal vs. AGS + PTH1R:Basal
  AGS:Basal vs. AGS + PTH1R:Forskolin (10 uM)
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3.5 No Induction of cAMP in Transfected mGEP Cells after PTHrP (1-36) 
Treatment 
Since there was a positive induction of cAMP after treating the transfected 
AGS cells with agonist PTHrP (1-36), we tried investigating if mGEP cell line will 
be able to induce cAMP and activate Gαs pathway thus having similar effect on 
signaling pathway like AGS cell line. There was no induction of cAMP in PTHrP (1-
36) treated and transfected mGEP cells, unlike AGS cells. Results show a positive 

















Figure 3.7: No cAMP induction in PTH1R transfected mGEP cells 
 
mGEP cells were transfected and treated with PTHrP (1-36) agonist 1μM. Forskolin 10μM was used to 
stimulate the production of cAMP as a positive control. Data represents no stimulation of cAMP after 
treating transfected mGEP cells with PTHrP agonist. Two-way ANOVA test was used for data analysis. 













3.6 PTHrP (1-36) Caused Phosphorylation of ERK 1/2 in Transfected mGEP 
Cells 
Transfected mGEP cells did not show any response in activating the Gαs 
signaling pathway by the induction of cAMP after PTHrP (1-36) treatment. Another 
possibility was to test the activation and phosphorylation of ERK pathway after 
treating the transfected mGEP cells with PTHrP (1-36). Transfected mGEP cells were 
treated with different concentrations of PTHrP (1-36) agonist for five minutes. 
Concentrations used (0.01 μM and 0.1 μM).  Results indicate a rapid activation and 
phosphorylation of ERK1/2 in transfected mGEP cells as shown in Figure 3.8.  
Phosphorylated ERK1/2 was compared to total ERK1/2 and the fold increase 
was calculated. Results indicate 22 fold increase of phosphorylated ERK1/2 compared 
to the total ERK1/2 in the transfected mGEP treated with 0.01μM PTHrP (1-36) for 
five minutes. Furthermore, results showed significant 36 fold increase of 
phosphorylated ERK1/2 compared to Total ERK1/2 in the transfected mGEP treated 

















Figure 3.8: The activation of ERK1/2 pathway in PTH1R transfected mGEP 
 
mGEP cells were transiently transfected for 48 hrs with PTH1R (2μg/well). Serum starved cells were 
treated with PTHrP (1-36) at two different doses (0.01 μM) and (0.1 μM) for five minutes before lysis. 
Bar graph represents the fold increase of pERK1/2 compared to Total ERK1/2. Highest fold increase 





































3.7 Effect of PTHrP (1-36) and PTHrP (7-34) on Transfected mGEP Cell Viability 
The effect of different concentrations of PTHrP (1-36) and PTHrP (7-34) at 
different times was tested on PTH1R transfected mGEP cell line shown in Figure 3.9. 
Concentrations varied from 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2.5, 5, and 10 μM. Although 
repeated several times, the results demonstrated inconsistency among the groups of 
each treatment (experiment repeated at least three times for both time points). There 
was a trend with slight increase after treatment with agonist at 24 hrs. However, this 



















Figure 3.9: Cellular viability of PTH1R transfected mGEP upon agonist and 
antagonist treatment for 24 and 48 hrs 
 
PTHrP (1-36) and PTHrP (7-34) did not show any consistent significance or results recorder at 24 hrs. 
and 48 hrs. Statistical analysis for cell viability data was performed using Two-way ANOVA test. 









3.8 Morphological Changes in mGEP Cells Treated with PTHrP (1-36) and 
PTHrP (7-34) 
Morphological observations of mGEP cells treated with PTHrP (1-36) as 
shown from (Figure 3.10 to Figure 3.13) and PTHrP (7-34) as shown from (Figure 
3.14 to Figure 3.17) for different times (6, 12, 24, and 48 hrs.) and different doses 
(0.01, 0.1, 0.2, 0.5, and 1 μM). Results show change in shape and structure between 
untransfected and transfected cells in different conditions. Different doses of each 
treatment did not show drastic morphological changes except for long connections and 
cell membranes connecting one cell to another. Rounding and shrinking of cells were 






























Figure 3.10: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 6 hrs 
 







































Figure 3.11: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 12 hrs 
 








































Figure 3.12: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 24 hrs 
 







































Figure 3.13: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 48 hrs 
 







































Figure 3.14: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 6 hrs 
 







































Figure 3.15: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 12 hrs 
 







































Figure 3.16: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 24 hrs 
 







































Figure 3.17: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 48 hrs 
 
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (7-34) treatment for 48 hrs. 









3.9 Expression of PTH1R Target Genes after PTHrP (1-36) Treatment 
Expression of PTH1R target genes were examined using Real Time-PCR after 
transfecting mGEP cells for 24 hrs., starved overnight, and then treated with PTHrP 
(1-36) for five minutes before extracting the RNA. The control cells used were 
transfected cells not treated with PTHrP (1-36).  
In the case for CaSR, FGF23, IL-6, and NHERF1, while comparing transfected 
mGEP to transfected and treated mGEP with PTHrP (1-36), there is no significance 
change in the gene expression. However, for the target gene LDLR, there was 
significant increase in transfected and treated mGEP cells in comparison with 
transfected mGEP cells. 
On the other hand, while comparing untransfected mGEP to transfected mGEP, 
there was a significant reduction of gene expression in CaSR, FGF23, IL-6, and 
NHERF1 in transfected mGEP. However, LDLR gene expression was upregulated in 







Figure 3.18: Relative mRNA expression of PTH1R target genes in mGEP cells 
 
RNA expression of PTH1R target genes was analyzed by Real Time-PCR in Untransfected mGEP, Transfected mGEP, Transfected and treated mGEP with PTHrP 










4. Chapter 4: Discussion 
PTH1R regulates calcium ion homeostasis in bones and kidneys, as supported 
by many extensive researches [29]. However, very limited studies focused on other 
regulatory and functional effects of PTH1R in the gastric system. 
In the present study, the expression of PTH1R in gastric epithelial cells both in 
vivo and in vitro was examined. Even though the expression was detected in normal 
human and mouse stomach as shown in Figure 3.1 and 3.2 respectively, the expression 
was not detected in cell lines representative of mouse gastric progenitor cells, and 
human gastric cancer cells.  
The absence of PTH1R expression in cells was managed by transfecting 
PTH1R into the cells. To confirm successful transfection, the cells were stained against 
PTH1R antibody, and the localization of the receptor was detected to be cytoplasmic 
and nuclear as shown in Figure 3.4 and Figure 3.5. Although PTH1R is a GPCR, which 
consists of large sequence of amino acids for its protein structure embedded in the cell 
membrane, yet studies reported its ability to localize into the cytoplasm and nucleus 
via its NLS which is shown in the diagram Figure 1.3, this is consistent with other 
studies [30,31] .   
PTH1R acts on multiple signaling pathways when it is stimulated  [29]. In our 
study, we found that the human gastric cancer cell line activated Gαs as shown in 
Figure 3.6. However, mouse gastric progenitor cells failed to induce Gαs Figure 3.7, 
and as such another signaling pathway was examined, and we confirmed the activation 
of ERK1/2 as shown in Figure 3.8. ERK1/2 is a known pathway for many endocrine 
cells and its importance in various cellular processes including proliferation has been 






overexpressed in patients with gastric cancer, this pathway represents an ideal target 
for generating therapeutic drugs for patients with gastric cancer as discussed in many 
articles [97,98].   
In a study, they reported that when one signaling pathway is activated, it might 
cause inhibition of other signaling pathways [38]. This concept is relatively new in 
GPCR, and is referred to as biased GPCR signaling [99]. Since the activation of 
different signaling pathways for PTH1R is studied, this shows that different activations 
might depend on cell type, ligand, and condition of the cell [100]. For example a study 
was conducted on HEK293 cells using a different PTH1R ligand, PTH (1-34) and was 
reported to induce ERK1/2, but when they used a synthetic and  modified ligand, PTH 
(1-36) which solely acts on Gαs pathway,  it failed to induce ERK1/2 and only activated 
Gαs [42].  In PTH1R, biased agonism involving β-arrestin that acts independently from 
GPCR mechanism  is a new therapeutic target  to improve osteoporosis therapy 
[101,102].  
Another result emerged at this point which is the presence of PTHLH in mGEP 
cells as shown in Figure 3.2B. We proposed a hypothesis which states that as soon as 
the mGEP cells are transfected with PTH1R, the cell will uptake its endogenous 
PTHLH and activate the receptor. The prolonged overstimulation and exposure of 
PTH1R to PTHLH will cause the receptor to reach its threshold and stop responding 
to any further PTHLH or PTH treatment. As such the transfection is transient for a 
time duration of 48 hrs, resulting in receptor desensitization and will thus activate 
ERK1/2 pathway. The desensitization of GPCRs has been documented in other studies 
as well which matches well with the proposed explanation above [38,42,103]. This 
result was further confirmed when we transfected mGEP cells and noted cAMP 






However, whether or not the ligand PTHLH did internalize into the cell along with the 
receptor, needs to be further examined since it was previously reported that PTHLH 
contains an NLS as well [45]. 
Collectively, our results can be explained by receptor desensitization. In the 
case of AGS cells, they do not express PTHLH as a ligand for PTH1R as reported in 
one study [36], neither do they express the receptor PTH1R based on our finding 
shown in Figure 3.1. Upon transfecting and treating the cells with PTHrP (1-36), the 
receptor was activated causing an induction in Gαs pathway producing cAMP as shown 
in Figure 3.6.  
Using this proposed hypothesis, we can explain the results found in cell 
viability as well, which resulted in inconsistent results as shown in Figure 3.9. 
However, the morphological changes of transfected mGEP treated with different 
concentrations of agonist and antagonist, as shown from Figure 3.10 showed larger 
cell to cell spaces and longer connections between cells. This needs to be further 
examined and investigated.  
 As for the target genes, no significant change was observed in CaSR, FGF23, 
IL6 and NHERF1 between PTH1R-transfected mGEP and transfected and PTHrP (1-
36) treated mGEP. This is also consistent with our previous findings in which we found 
no significant change between transfected mGEP cells and transfected and treated 
mGEP cells. Moreover, the significant change for the above mentioned target genes 
were while comparing PTH1R-transfected mGEP with untransfected mGEP. 
However, it is important to note that there was a significant upregulation of LDLR in 
treated and PTH1R transfected mGEP in comparison with transfected mGEP. 
Results showed a down regulation of CaSR, FGF23, IL-6 and NHERF1 in 






in a negative feedback loop, in which it is supported by other studies [77], increased 
calcium levels in the blood can be sensed by CaSR which will downregulate and inhibit 
PTH1R from activating bone resorption to secrete more calcium in the blood. We 
report a similar finding in which after 48 hrs of transfection, the negative feedback 
loop for transfected mGEP cells caused the downregulation of the target genes in order 
to maintain gastric calcium homeostasis as shown in Figure 3.18. 
IL-6 and NHERF1 both showed a downregulation in PTH1R transfected mGEP 
cells in comparison to untransfected mGEP cells. IL-6 is previously reported to be 
upregulated by PTHLH in cancer patients [80]. NHERF1 is thought to inhibit PTH1R 
desensitization [79,80]. My results could be explained as that in transfected mGEP 
cells expressing PTH1R, NHERF1 is being used up by the cells in order to inhibit 
PTH1R desensitization. This can be further illustrated in a slight increase in NHERF1 
gene expression in transfected and PTHrP (1-36) treated mGEP cells. 
 LDLR showed a significant upregulation in PTH1R transfected and treated 
mGEP cells in comparison to only PTH1R transfected cells. It is known from previous 
research that PTH can induce LDLR [80]. LDLR is known to act via the Wnt signaling 
pathway [104]. It has been also reported that PTH1R can act on the Wnt pathway along 
with the frizzled GPCRs to regulate bone formation [105]. The Wnt pathway is a 
pharmaceutical target to treat many different cancers [106]. Briefly, Wnt pathway 
functions by activating either canonical or non-canonical pathway. In the case of non-
canonical pathway, it is activated by LDLR and frizzled receptors. This will be 
followed by a cascade of stimulations leading to activation of different Wnt target 
genes which plays important roles in cellular regulation [106]. This shows that PTH1R 
activation might suppress and downregulate other target genes in order to activate the 






of action and more details on this crosstalk which highlights the importance of 
cholesterol and lipoprotein with PTH1R activation needs to be further investigated, 






5. Chapter 5: Conclusion and Future Directions 
 
 
The present study aimed to determine the normal expression in vivo on mice 
and the, function and role of PTH1R in gastric epithelium in vitro on mGEP (mouse) 
and AGS (human) cells. These aims were established by further studying the signaling 
pathway of PTH1R and the mechanism of induction in the gastric epithelial cells. 
Overall findings are shown in figure 5.1. 
Our in vivo results showed positive expression of PTH1R on both 
transcriptional and translational levels in the forestomach, corpus, and antrum of the 
gastric epithelium of wild type mice. Another important in vivo result was the 
expression of PTH1R in normal human stomach. 
Our in vitro results were subdivided into two, where we tested the signaling 
pathway of AGS and mGEP mouse cell lines. In the case of AGS, cAMP was induced 
in PTH1R transfected and PTHrP (1-36) treated cells. mGEP cells, on the other hand, 
showed expression of the ligand PTHLH, and PTH1R transfected and PTHrP (1-36) 
treated mGEP cells did not induce cAMP, in fact pERK1/2 was reported which is 
highly linked to receptor desensitization. 
Target genes were also investigated in this study, and while comparing 
untransfected mGEP cells to transfected mGEP cells, significant downregulation was 
reported in CaSR, FGF23, IL6, and NHERF1. On the other hand, upregulation of 
LDLR in PTH1R transfected and treated mGEP cells in comparison with transfected 
mGEP. Collectively, these results showed the importance of PTH1R in maintaining 
and regulating gastric epithelium. 
PTH1R is not highly studied in the gastric glands. One of our interesting results 






of the receptor needs to be further investigated by conducting immune co-staining of 
different types of gastric cells and PTH1R. Especially, since previous findings 
illustrate cAMP importance in regulating parietal cells to secrete gastric acid. It will 
be novel to identify the exact location of PTH1R and whether or not it is expressed in 
parietal cells, since these cells also express PTHLH. This might propose a functional 
mechanism to identify PTHLH autocrine regulatory role in maintaining gastric 
homeostasis. 
   PTH1R is a GPCR which was identified with NLS in the C terminal as 
previously reported; however, no further research examined how this sequence 
functions in the stomach and its role in comparison to normal receptor activation. 
Investigating this issue by creating a PTH1R C terminal knock out might highlight 
new modified signaling mechanism in response to specific ligand-binding sites. 
Moreover, PTHLH contains NLS as well, it would be interesting to examine by co-
precipitation if PTHLH will internalize with PTH1R in any specific signaling system. 
Our morphological study showed difference between transfected mGEP and 
untransfected mGEP cells. A future study aiming the use of electron microscopy to 
detect the changes inside the cell will be beneficial in understanding the morphological 
changes. 
In this study, the only two pathways studied were Gαs and ERK1/2. It is vital 
to study the other signaling pathways as the receptor can act otherwise in different 
organs and systems using different agonists. Also, one of the aims in future directions 
could be testing the phosphorylation of ERK1/2 using western blot at different time 
points after treating the cells with PTHrP (1-36). In this study, PTHrP (1-36) agonist 
was used to stimulate PTH1R, however, other agonists exist such as PTH (1-34), and 






Since the focus of this project was on PTH1R in the gastric gland, very little 
studies were available to compare our results to. More research needs to be conducted 
on gastric cancer and the signaling pathway that is activated when PTH1R expression 
is upregulated. 
To overcome the endogenous PTHLH effect on cells and its alteration of the 
results, it will be a better option to use AGS transfected cells since it does not express 
PTHLH, this will lead to more consistent results.  
The target genes investigated in this thesis were CaSR, FGF23, IL6, LDLR, 
and NHERF1 by Real-Time PCR. It is important to investigate more target genes in 
the future to be able to examine the overall change in the gastric system. For this 
project, only 0.1 µM which is a small concentration of PTHrP (1-36) was used in 
treating transfected mGEP cells for five minutes only. Other concentrations and 
different times should be further studied. Creating a detailed time and dose study to 
confirm the hypothesis of desensitization in the RT-PCR experiment will be helpful. 
Also, treating the transfected mGEP cells with an antagonist PTHrP (7-34) should 
restore the gene expression of the target genes. 
Finally, PTH1R in vitro study on gastric cell lines showed change and 
induction of several signaling pathways and target genes. Conducting further studies 
on the importance of PTH1R in gastric glands in vivo would be very interesting, either 
by knockdown of PTH1R, or treating wild type mice of different ages with PTH1R 
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